Other: Clinical Trials

4 trials of Other, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 not yet recruiting, 1 recruiting, 1 terminated. 4 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Completed 1, Not yet recruiting 1, Recruiting 1, Terminated 1
Phase 11Terminated 1

Follow Other: new trials by email Literature Review of Other trials Research Report on Other

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
Cemiplimab, cemiplimab plus fianlimab, cemiplimab + REGN7075 - Colo-rectal Cancer
Phase 2RecruitingNSABP Foundation Inc792026-04-172026-09-03
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour
Phase 2Not yet recruitingPeking University Shenzhen Hospital2002025-01-012024-11-18
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer
D-1553, Other - NSCLC
Phase 1 / Phase 2TerminatedInventisBio Co., Ltd222022-09-132024-10-15
Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
AIN457A, Other - Psoriatic Arthritis
Phase 2CompletedNovartis Pharmaceuticals282010-06-012021-06-10

Conditions studied

Arthritis, Psoriatic (1)  ·  Colonic Neoplasms (1)

Sponsors

InventisBio Co., Ltd (1)  ·  NSABP Foundation Inc (1)  ·  Novartis Pharmaceuticals (1)  ·  Peking University Shenzhen Hospital (1)

Countries

China (1)  ·  Germany (1)  ·  Netherlands (1)  ·  United Kingdom (1)  ·  United States (1)

Results publications

PMID 42345857